GPT and metabolic dysfunction-associated steatotic liver disease: High-risk NAFLD patients (n = 40 with available labs) had mean ALT of 55.1 U/L (range 14–111, SD = 21.6) vs. 66.5 U/L (range 10–287, SD = 43.8) for the remaining NAFLD patients (n = 179 with available labs) (p = 0.295 [based on chi-square for Wilcoxon rank-sum statistic]). Data were available to calculate a NAFLD Fibrosis Score in 154/632, most of whom (80.6%) were in the low or indeterminate risk categories (Fig. 2).